Integra LifeSciences Holdings Corp. (NASDAQ:IART) has been given an average recommendation of “Buy” by the nine analysts that are covering the stock. Two investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $93.83.

Several equities research analysts have weighed in on the stock. Zacks Investment Research raised shares of Integra LifeSciences Holdings Corp. from a “sell” rating to a “hold” rating in a research note on Monday, October 31st. TheStreet raised shares of Integra LifeSciences Holdings Corp. from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 27th. Oppenheimer Holdings Inc. set a $93.00 price target on shares of Integra LifeSciences Holdings Corp. and gave the company a “buy” rating in a research note on Friday, October 28th. Lake Street Capital raised shares of Integra LifeSciences Holdings Corp. from a “hold” rating to a “buy” rating and set a $92.00 price target for the company in a research note on Friday, October 28th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $95.00 price target on shares of Integra LifeSciences Holdings Corp. in a research note on Tuesday, September 27th.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded down 0.93% during trading on Wednesday, hitting $80.81. 214,594 shares of the stock were exchanged. Integra LifeSciences Holdings Corp. has a 52 week low of $54.75 and a 52 week high of $88.86. The stock has a 50 day moving average of $80.69 and a 200-day moving average of $80.82. The stock has a market cap of $3.02 billion, a P/E ratio of 52.64 and a beta of 0.76.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last posted its quarterly earnings results on Thursday, October 27th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.04. Integra LifeSciences Holdings Corp. had a net margin of 6.09% and a return on equity of 16.11%. The firm earned $250.30 million during the quarter, compared to the consensus estimate of $249.30 million. During the same period in the previous year, the firm posted $0.75 earnings per share. The business’s revenue was up 10.6% compared to the same quarter last year. Equities analysts expect that Integra LifeSciences Holdings Corp. will post $3.50 EPS for the current fiscal year.

WARNING: “Integra LifeSciences Holdings Corp. (IART) Given Average Rating of “Buy” by Analysts” was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/30/integra-lifesciences-holdings-corp-iart-given-average-rating-of-buy-by-analysts.html.

In related news, CEO Peter J. Arduini sold 24,009 shares of the business’s stock in a transaction dated Tuesday, November 8th. The shares were sold at an average price of $79.51, for a total transaction of $1,908,955.59. Following the transaction, the chief executive officer now directly owns 25,593 shares in the company, valued at $2,034,899.43. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 21.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can boosted its position in Integra LifeSciences Holdings Corp. by 7.0% in the third quarter. Great West Life Assurance Co. Can now owns 40,880 shares of the company’s stock valued at $3,373,000 after buying an additional 2,685 shares during the period. Falcon Point Capital LLC boosted its position in Integra LifeSciences Holdings Corp. by 6.3% in the second quarter. Falcon Point Capital LLC now owns 134,293 shares of the company’s stock valued at $10,714,000 after buying an additional 7,934 shares during the period. Mesirow Financial Investment Management Equity Management purchased a new position in Integra LifeSciences Holdings Corp. during the second quarter valued at $10,359,000. RS Investment Management Co. LLC purchased a new position in Integra LifeSciences Holdings Corp. during the second quarter valued at $56,604,000. Finally, Quantitative Systematic Strategies LLC purchased a new position in Integra LifeSciences Holdings Corp. during the second quarter valued at $402,000. Institutional investors and hedge funds own 90.19% of the company’s stock.

About Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

5 Day Chart for NASDAQ:IART

Receive News & Stock Ratings for Integra LifeSciences Holdings Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corp. and related stocks with our FREE daily email newsletter.